The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
News|Articles|January 9, 2017
Takeda to Acquire ARIAD
Author(s)Pharmaceutical Technology Editors
Takeda will acquire ARIAD Pharmaceuticals for approximately $5.2 billion.
Advertisement
On Jan. 9, 2017, Takeda announced plans to acquire ARIAD Pharmaceuticals for $24 per share in cash, or approximately $5.2 billion. The acquisition of ARIAD brings two targeted therapies that will expand Takeda’s existing oncology portfolio. The transaction is expected to close by the end of February 2017.
Under the terms of the agreement, Takeda will acquire birgatinib and Iclusig from ARIAD. Brigatinib is an investigational drug product for the treatment of a genetically-defined subpopulation of non-small cell lung cancer. Iclusig is a treatment for chronic myeloid leukemia and a subset of acute lymphoblastic leukemia. These two targeted therapies will position Takeda for long-term growth in oncology, the company said in a
ARIAD provided calendar year 2016 revenue guidance for Iclusig of $170-180 million, and Takeda expects significant long-term revenue potential from the two lead assets. Takeda will leverage ARIAD’s R&D capabilities and platform, and largely absorb its R&D costs within Takeda's existing R&D budget.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Advertisement
Advertisement